Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors.
about
Mechanism of activation and inhibition of the HER4/ErbB4 kinaseStructures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinasesStructural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 ProteinA systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expressionComputational delineation of tyrosyl-substrate recognition and catalytic landscapes by the epidermal growth factor receptor tyrosine kinase domain.Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancerA highly efficient peptide substrate for EGFR activates the kinase by inducing aggregationHer4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro systemA multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformationsAnalytical reduction of combinatorial complexity arising from multiple protein modification sites.Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinibNeuregulin-1 modulates hippocampal gamma oscillations: implications for schizophrenia.Activation of the epidermal growth factor receptor promotes lymphangiogenesis in the skin.In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity.Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer.Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism.Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.In vitro activation and inhibition of recombinant EGFR tyrosine kinase expressed in Escherichia coli.
P2860
Q24310089-28CC097E-CE3F-45F7-92B2-A3088D7B89E6Q27644014-0BCCA522-5778-4608-B7FB-73219F4B071DQ27649889-94C9A8E7-EF5A-42CA-9BCE-29DCC2A4BB5FQ27667382-5969D7EE-D382-4589-BFAB-9CC76BFB5F06Q27852979-4B9B0B80-241F-4563-8B06-3D643ED1FFDBQ28484612-31705127-6042-490C-99AB-FCC1BBCEC989Q30581942-1EDE8D74-3598-43AD-A58A-B35AF6F3AE0CQ33576845-79386B8C-FDBF-4251-8A49-814C3C0B0B71Q33723892-7AFF9E5B-2550-4090-8C7F-B6852B6C615AQ33747967-F4E329DD-D93D-4790-A4A5-DBA2DE0274CCQ34492884-CE03A1DE-3552-41E5-9906-4E2117B3A42AQ35009393-5FFE0939-C5DE-4F1B-8D65-ADBEF1B990B1Q35992870-B67EFE4E-2DAC-48C2-BDB4-28991FBE0785Q37090102-359ED52E-D664-4448-875A-7E9D95CE7AD7Q37100821-CEB4C4C0-FC4F-4118-A61D-4C27B73A8A57Q39839427-3CB09623-FFB8-4B1D-AA5E-6093B995A03EQ40678332-DB0CBA71-39D7-41C5-AE71-D4E442D5EFBBQ41147805-7B1E9F00-3A0F-4933-8502-B5B7B33CBBF4Q46881384-080AC360-A10C-47AD-912F-196163CD0D7FQ48922155-7E9BF03B-7941-4EED-853E-8E09E5FD4B8CQ52590998-7A311001-8F5E-4DEE-99C2-44BC1B2E2921Q54301166-C45AC69F-C462-4507-A74E-887DF31A4EFC
P2860
Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Comparison of the biochemical ...... sitivity to kinase inhibitors.
@en
type
label
Comparison of the biochemical ...... sitivity to kinase inhibitors.
@en
prefLabel
Comparison of the biochemical ...... sitivity to kinase inhibitors.
@en
P2093
P2860
P356
P1476
Comparison of the biochemical ...... sitivity to kinase inhibitors.
@en
P2093
Christine Hoffman
Earnest Horne
Edgar R Wood
H Luke Carter
J Darren Stuart
Karen Lackey
Kevin Blackburn
Krystal J Alligood
Mary B Moyer
Perry S Brignola
P2860
P304
P356
10.1074/JBC.M105907200
P407
P577
2001-11-05T00:00:00Z